Amphastar Pharmaceuticals (AMPH) vs Harrow (HROW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amphastar Pharmaceuticals (AMPH) has outperformed Harrow (HROW) over the past year, gaining 8.6% versus a loss of 21.8%. Over five years, HROW leads with a +196.1% price change compared with +41.9% for AMPH. Amphastar Pharmaceuticals is the larger company by market cap ($1.20 billion vs $1.14 billion), about 1.1 times the size, while Harrow is growing revenue faster (+36.4% vs -1.7%).
On valuation, Amphastar Pharmaceuticals trades at a lower forward P/E (8.4x vs 16.3x for Harrow). Amphastar Pharmaceuticals converts more of its revenue into profit, with a net margin of 13.6% versus -1.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | HROW |
|---|---|---|
| Share price | $28.25 | $30.41 |
| Market cap | $1.20B | $1.14B |
| 1-day change | +0.50% | -5.35% |
| YTD return | +5.49% | -37.94% |
| 1-year return | +8.61% | -21.85% |
| 5-year return | +41.89% | +196.11% |
| P/E ratio (TTM) | 12.96 | — |
| Forward P/E | 8.43 | 16.26 |
| EPS (TTM) | $2.18 | $-0.76 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $719.89M | $272.30M |
| Revenue growth (YoY) | -1.65% | +36.41% |
| Net income (latest FY) | $98.09M | $-5.14M |
| Gross margin | 49.46% | 75.05% |
| Operating margin | 19.50% | 11.21% |
| Net margin | 13.63% | -1.89% |
| 52-week high | $31.00 | $54.85 |
| 52-week low | $16.65 | $25.76 |
| Distance from 52-week high | -8.87% | -44.56% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | -13.27% | +104.70% |
| Average volume | 475.35K | 626.20K |
| Shares outstanding | 42.65M | 37.53M |
| Employees | 1,976 | 373 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMPH has outperformed HROW by 30.5 percentage points over the past year.
- Amphastar Pharmaceuticals is more profitable, keeping 13.6 cents of every revenue dollar as net income versus -1.9 cents for Harrow.
- Harrow grew revenue faster in its latest fiscal year (+36.41% vs -1.65%).
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
AMPH vs HROW FAQ
Which is bigger, Amphastar Pharmaceuticals or Harrow?
Amphastar Pharmaceuticals (AMPH) is larger, with a market capitalization of $1.20B compared with $1.14B for Harrow (HROW).
Which stock has performed better over the past year, AMPH or HROW?
AMPH returned +8.61% over the past 12 months, compared with -21.85% for HROW (price return, excluding dividends). Past performance does not predict future results.
Are Amphastar Pharmaceuticals and Harrow in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.